Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Early Endosome: Endocytosis of Transferrin01:28

The Early Endosome: Endocytosis of Transferrin

3.3K
Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
3.3K
The Periodic Table and Organismal Elements00:57

The Periodic Table and Organismal Elements

180.2K
Overview
180.2K
Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

3.3K
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
3.3K
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

1.0K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
1.0K
Lifecycle of Erythrocytes01:22

Lifecycle of Erythrocytes

2.0K
Erythrocytes, also known as red blood cells, constantly move through blood capillaries. As a result, they damage their plasma membrane due to the continuous friction. Typically, after 100 to 120 days, erythrocytes become rigid and fragile as they wear out. As they pass through small vessels in the spleen and liver, they can get trapped and break apart into fragments.
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups....
2.0K
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

100
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
100

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fetal factors disrupt placental and maternal iron homeostasis in murine β-thalassemia.

Blood·2023
Same author

Corrigendum: Iron and Cadmium Entry Into Renal Mitochondria: Physiological and Toxicological Implications.

Frontiers in cell and developmental biology·2021
Same author

Correction to: Iron chelation may harm patients with COVID-19.

European journal of clinical pharmacology·2021
Same author

Iron and Cadmium Entry Into Renal Mitochondria: Physiological and Toxicological Implications.

Frontiers in cell and developmental biology·2020
Same author

Iron chelation may harm patients with COVID-19.

European journal of clinical pharmacology·2020
Same author

Animal Models of Normal and Disturbed Iron and Copper Metabolism.

The Journal of nutrition·2019
Same journal

Nanomedicine strategies targeting STAT3 in cancer: From tumor suppression to microenvironment modulation.

The Journal of pharmacology and experimental therapeutics·2026
Same journal

Inflammasome formation and interleukin-1β secretion are reduced in peripheral blood monocytes from HIV+ cannabis users.

The Journal of pharmacology and experimental therapeutics·2026
Same journal

Arginine vasopressin: A promising therapeutic target for metabolic syndrome.

The Journal of pharmacology and experimental therapeutics·2026
Same journal

Structure-based prediction of muscarinic M1/M3 receptor antagonist activity: Curated dataset and scaffold-aware evaluation.

The Journal of pharmacology and experimental therapeutics·2026
Same journal

DSP-2342, a novel 5-hydroxytryptamine 2A/7 receptor antagonist, has therapeutic potential for behavioral and psychological symptoms of dementia.

The Journal of pharmacology and experimental therapeutics·2026
Same journal

Destabilization of TIP60-PXR complex by rifampicin impairs wound-induced cell migration.

The Journal of pharmacology and experimental therapeutics·2026
See all related articles

Related Experiment Video

Updated: Jul 26, 2025

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.6K

Managing Iron Overload: A Gut Check.

Michael D Garrick1

  • 1Department of Biochemistry, University at Buffalo, Buffalo, New York mgarrick@buffalo.edu.

The Journal of Pharmacology and Experimental Therapeutics
|June 15, 2023
PubMed
Summary
This summary is machine-generated.

Divalent metal transporter 1 (DMT1) inhibitors show promise for studying iron homeostasis but face toxicity challenges. Further research is needed for developing safe treatments for iron overload disorders.

More Related Videos

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
05:36

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

518
Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

2.0K

Related Experiment Videos

Last Updated: Jul 26, 2025

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.6K
Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
05:36

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

518
Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes
08:45

Quantitating Iron Transport Across the Mouse Placenta In Vivo Using Nonradioactive Iron Isotopes

Published on: May 10, 2022

2.0K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Physiology

Background:

  • Divalent metal transporter 1 (DMT1) is crucial for iron absorption in the duodenum.
  • Developing specific DMT1 inhibitors is key for understanding iron homeostasis and treating iron overload disorders.
  • Challenges include DMT1's widespread tissue expression and transport of multiple metal ions.

Purpose of the Study:

  • To evaluate the efforts of Xenon Pharmaceuticals in developing DMT1 inhibitors.
  • To assess the utility of XEN601 and XEN602 as research tools.
  • To consider alternative strategies for treating iron overload disorders.

Main Methods:

  • Review of published research on DMT1 inhibitors, specifically XEN601 and XEN602.
  • Analysis of reported efficacy and toxicity of these compounds.
  • Exploration of alternative therapeutic approaches.

Main Results:

  • Xenon Pharmaceuticals developed potent DMT1 inhibitors, XEN601 and XEN602.
  • These inhibitors have demonstrated significant utility as research tools for studying metal ion homeostasis.
  • However, the compounds exhibit toxicity, leading to the cessation of their development for therapeutic use.

Conclusions:

  • Xenon's DMT1 inhibitors are valuable for research but not viable for treating iron overload disorders due to toxicity.
  • Alternative strategies are required to develop safe and effective pharmacological treatments for iron overload conditions.
  • Continued research into DMT1 function and inhibition remains critical for advancing therapeutic options.